Hello, Fool! | Login | Signup | My Fool
Oct 8, 2008 7:05 AM ET | Feedback | Site Changes | Help
A pharmaceutical company focused on developing products which can provide improved efficacy, safety or patient convenience in the treatment of acute and chronic pain and pain related conditions.
View Ticker Page (POZN)
Results 1 - 10 of 22 : 123
Recs
everclear08 (< 20) Submitted: 3/14/08 11:11 AM : Start Price: $10.51 POZN Score: 5.09
FDA concerns about tox have been addressed according to publicly available data. Given that the concern was addressed and seemingly negated, it would seem approval is right around the corner. Word of Caution: You can never p...
Report this Post Replies: 0 | Reply | Permalink
Oops! There appears to be a problem with your comment. Check to see if there's something you left out.
tenmiles (99.99) Submitted: 8/01/07 2:57 PM : Start Price: $17.11 POZN Score: -18.80
Expect Trexima to be approved - riskly play but $billion market potential.
boater9384 (< 20) Submitted: 1/29/08 8:26 PM : Start Price: $12.13 POZN Score: -2.72
Check out Zack's calling this the stock of the week.
TechnicalTommy (< 20) Submitted: 1/17/07 9:28 AM : Start Price: $16.62 POZN Score: -18.16
52 week high soon
CplDad (20.57) Submitted: 1/22/08 11:13 AM : Start Price: $12.51 POZN Score: -7.01
One of several picks. I am testing a new screen to find high potential but weak performing stocks. We'll see how they go...
steelpoker (< 20) Submitted: 2/22/08 4:39 PM : Start Price: $12.29 POZN Score: -3.66
Product will be FDA approved... = blockbuster.
rwh999 (58.24) Submitted: 3/12/08 1:20 AM : Start Price: $10.29 POZN Score: 8.41
Will the FDA make POZN shine? Third times a charm.
zoiebelle (35.92) Submitted: 6/04/08 9:30 PM : Start Price: $13.88 POZN Score: -9.98
medical treatment process technology breakthrough.
corkymilb (< 20) Submitted: 7/06/08 11:27 AM : Start Price: $10.09 POZN Score: 6.56
effective drug with a lot of GSK marketing behind it.
philsie1 (< 20) Submitted: 7/07/08 1:33 PM : Start Price: $9.61 POZN Score: 9.21
Undervalued per earnings potential of Treximet and pipeline including PN and PA. Many catalysts coming in next couple months, sales data on Treximet, partner for PA and SPA acceptance. PN data later in year or early next year.
Terms & Conditions
RSS Headlines
Fool UK